Archive
This is a library of Lhasa's blog articles.
Filter by Category
Filter by Author
- Alex Cayley
- Alex Harding
- Ally Reeves
- Alun Myden
- Anax Oliveira
- Andrew Thresher
- Ash Ali
- Cheuk Man Tsang
- Chris Barber
- Crina Heghes
- Daragh Connolly
- Dave Yeo
- David Ponting
- Emma Scrafton
- Fabrizio Campo
- Fernanda Waechter
- Grace Kocks
- Hazel Gardiner
- James McManus
- Jess Tidmarsh
- Jessica Magallanes-Castaneda
- Josh Cosby
- Kelly Gallagher
- Laura Johnston
- Liz Covey-Crump
- Martyn Chilton
- Michael Burns
- Nik Marchetti
- Oana Leonte
- Paul Imeson
- Pearl Saville
- Rachael Tennant
- Rachel Hemingway
- Raeesah Saddiq
- Rob Foster
- Sara Atkinson
- Scott McDonald
- Susanne Stalford
Filter by Product
Supporting N-nitrosamine risk assessments for drug products
N-Nitrosamine risk assessment and control have become an integral part of pharmaceutical drug product development. In this article, we discuss 3 key stages of risk assessment: identifying the source of risk, determining the level of activity and mitigating the risk. Discover how our in silico tools can be used to support informed decision making on chemical safety, in this blog article.
25 July 2022
Controlling potentially mutagenic impurities – 8 top tips from industry experts
A key consideration within drug substance synthesis is the potential presence of mutagenic impurities. Potentially mutagenic impurities (PMIs) often arise from reagents which are essential for the synthesis of a final active pharmaceutical ingredient (API) meaning that the risk is therefore often unavoidable. As a result, there is a need to assess the risk posed by mutagenic impurities.
To discuss this topic in more detail, we were delighted to welcome Andrew Teasdale PhD and Muzaffar Khan PhD, to present at our webinar; Controlling potentially mutagenic impurities - hear from industry experts!In case you missed this event, we have summarised the top eight take away tips from the webinar, for quick and easy consumption within this article.
04 April 2022
20 tips for nitrosamine impurity assessment
Many readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!
05 August 2021
10 tips for controlling your potentially mutagenic impurities outside the lab
Many readers of this blog will be aware of the threat posed by potentially mutagenic impurities within drug substance synthesis. Such impurities often arise from reagents which are critical to the synthesis therefore this impurity-related threat is unavoidable.
As such, there is a need to assess the risk posed by mutagenic impurities.
30 June 2021
A day in the life of a Scientist at Lhasa Limited
Discover a day in the life of a Mirabilis Research Scientist at Lhasa Limited!
28 May 2021
Moving with the times; Lhasa’s cloud offerings
In a world where we are all striving for progress, technology is also advancing quickly.
Like many organisations across the life sciences industry – evidenced by the 82 Amazon Web Service (AWS) life sciences case studies - Lhasa has adopted cloud, Software as a Service (SaaS), options across three notable areas...
30 March 2021
Lhasa Limited collaborates with industry and regulators to define solubility purge best practice
Key to the regulatory acceptance of purge arguments is the conservatism within the purge factor scoring system, which for reactivity purge has been demonstrated across a number of publications and is consistently implemented across the pharmaceutical industry through the development of a collective understanding of and how they should be applied.
Likewise, when volatility purge scoring is relatively simple to understand and apply, particularly using the scoring thresholds originally proposed by Teasdale et al.
However, through our interactions with Mirabilis users, regulators, and other members of the purge community, it has become increasingly apparent that the same cannot be said of solubility purge scoring. Lhasa have therefore identified the huge value to the community of developing an accepted best practice, incorporating both the application of solubility purge scoring and, where appropriate, provision of a clear justification of the purge factor assigned.
29 October 2020
Anticipating and supporting the needs of our members
As a member-based organisation, anticipating and supporting the needs of our members is critical.
31 July 2020
Lhasa Limited supports the global challenge of nitrosamine impurity assessment
The recent discovery of N-nitrosamine (nitrosamine) impurities in several marketed pharmaceuticals has led to a requirement for further investigation into nitrosamine mutagenic and carcinogenic activity. Regulatory requirements mean that marketing authorisation holders for human medicines, containing chemically synthesised active substances, must review their medicines for the possible presence of nitrosamines and test all products at risk. Risk-based approaches to prioritise evaluations and subsequent confirmatory testing may be used. These assessments must be completed by October 2020, generating a significant challenge for the pharmaceutical industry.
13 July 2020